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Urinary excretion of nonesterified (NEC) and total cholesterol (TC) has been 
investigated in 79 patients with prostatic adenoma (BPH) and 48 patients with 
carcinoma of the prostate. Normal range of NEC was determined in 62 healthy 
individuals and was found to be 0.26-2.2 mg/24 hours (2 SD) with a mean 
value of 0.76 mg/24 hours. TC ranged from 0.3-2.9 mg124 hours with a mean 
value of 0.92 mg/24 hours. In benign prostatic hyperplasia normal values for 
NEC and TC were determined in stages without residual urine. In contrast 
patients with BPH and residual urine showed elevated NEC in 42.1% and 
elevated TC in 61.4%. In prostatic carcinoma NEC hyperexcretion was present 
in 44.8% of stage A and B and in 52.6% of stage C and D. TC was elevated 
in 52.2% and 63.2%, respectively. Simultaneous determination of NEC and 
serum acid phosphatase (SAP) gave a pathologic result of at least one param- 
eter in 51.7% of stage A and B and in 84.2% of stage C and D. If TC 
and serum acid phosphatase were combined, percentage of elevated values 
increases to 62.1 of stage A and B and was identical with 84.2 of stage C and 
D. If BPH with residual urine and other known conditions of urinary choles- 
terol hyperexcretion in males, pluripotential malignant testicular neoplasms 
and diseases of kidney and urinary tract, can be excluded with reasonable 
certainty, both parameters may be of value in diagnosis of prostatic cancer 
in even early clinical stages of the disease, especially in combination with 
the determination of SAP. 
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YPEREXCRETION OF URINARY NONESTERI- H FIED (NEC) or total cholesterol (TC) 
in prostatic cancer has been reported re- 
~ent ly .~*"  It was concluded that both param- 
eters are valuable in the diagnosis of the 
disease. A comparative evaluation of NEC and 
TC has not yet been undertaken; in addition, 
the performed studies did not show the value 
of these parameters in diagnosis of early 
clinical stages. Other known common condi- 
tions of urinary cholesterol hyperexcretion in 
males are pluripotential testicular neoplasms, 
diseases of kidney and urinary tract and benign 
prostatic h y p e r p l a ~ i a . ~ J ~ ~ ' ~ , ~ * J ~  In regard to 
the frequency of BPH in comparison to pros- 
tatic carcinoma, it was additionally necessary 
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to investigate whether elevated levels of 
urinary cholesterol were present in all clinical 
stages of BPH or only in patients with BPH 
and residual urine with indication for surgical 
treatment. 
MATERIALS AND METHODS 
Nonesterified and total urinary cholesterol 
were analyzed in 2 ml aliquots of 24-hour 
urine. After extraction with 6 ml ethyl acetate 
for 30 minutes in a rotating system, the uri- 
nary phase was removed. The ethyl acetate 
extract was purified with alkali (2 ml 0 . 1 ~  
NaOH) and water washings and dried under 
a stream of nitrogen. The residue was dissolved 
with 0.1 ml of the internal standard solution 
(10 mg 4-androstene-3, 17-dione/dl isooctane), 
followed by GLC on a 180 cm 1 % XE 60 col- 
umn, i.d. 2 mm, temp. const. 220 C. Quantita- 
tion was performed due to the peak height 
ratio, since alterations of cholesterol and 4- 
androstenedione concentration gave a linear 
response. 
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FIG. 1. Urinary excretion of nonesterified and 
TC was measured as above including hy- 
drolysis of the dried extract with 0.1 ml 3 N  
KOH and 0.9 ml ethanol for 60 minutes at 
60 C. NEC and TC were measured with an 
intraassay variance of 2.3% and 5.6% and an 
interassay variance of 11.2% and 10.9%, re- 
spectively. Specificity of the method was con- 
firmed by simultaneous masspectrographic 
analysis in selected samples. 
Clinical Material 
The clinical material consisted of patients 
with histopathologically proven prostatic neo- 
plasms, which were divided in clinical stages 
A-D according to Flocks. 11 patients were 
found to have a palpable prostatic nodule 
(stage A); in 18 patients the prostatic cancer 
was not nodular but confirmed to one lobe 
of the gland (stage B). 5 patients showed local 
extension outside of prostate (stage C); in 14 
cases metastasis in pelvis, other bones or lung 
were present. When urinary cholesterol de- 
terminations were performed, patients did 
not receive any treatment. A diagnosis of 
prostatic cancer had been established in most 
cases at the time of the investigation. 
22 patients with BPH were diagnosed by 
rectal examination; they were without any 
symptoms (stage 0) or showed pollakiuria and 
impaired urinary stream (stage 1). Residual 
urine was excluded in all these cases. In 57 
patients with BPH diagnosis was histopatho- 
logically proven after transurethral resection 























ent (stage 2); in some combined with urinary 
incontinence or secondary kidney damage 
(stage 3). 
The normal range for NEC and TC ex- 
cretion was calculated using standard pro- 
cedures and was obtained from a group of 




This group comprised 62 clinically healthy, 
asymptomatic and biochemically normal male 
individuals covering an age range of 14 to 
76 years. 
The excretion values for NEC and TC are 
illustrated in Fig. 1. Statistical analysis of the 
results obtained gave a mean excretion of 
0.76 mg/24 hours NEC and 0.92 mg/24 hours 
TC. The range for normal values was cal- 
culated as the mean k 2 SD including 95% of 
the population. On the basis of these results, 
the upper normal limit of the urinary excre- 
tion of NEC was considered to be 2.2 mg/24 
hours and for TC to be 2.9 mgi24 hours. Hy- 
perexcretion in the male, therefore, was de- 
fined as any result exceeding this value. It is 
important to note that the values of excretion 
of this group presented a log normal distri- 
bution. 
Prostatic Hyperplasia 
The results obtained in the study of 79 pa- 
tients with a diagnosis of adenomatous pros- 
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FIG. 3. Urinary excretion of nonesterified cholesterol in patients with prostatic carcinoma stage A-D. 
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tatic hyperplasia are presented in Fig. 2. J t  is 
remarkable that in the 22 patients with stage 
0- 1 NEC and T C  values were normal in con- 
trast to the 57 patients with stage 2-3 who 
revealed elevated NEC in 42.1% and elevated 
TC in 61.4%. DISCUSSION 
(Fig. 7). If T C  and serum acid phosphatase 
were combined, percentage of elevated values 
increased to 62.1 of stage A and B and was 
identical with 84.2 in stage C and D (Fig. 8). 
Adenocarcinoma of the Prostate 
The NEC and T C  values of 48 patients with 
prostatic carcinoma are illustrated in Figs. 3- 
6. The diagnosis was made on tissue obtained 
by needle biopsy or after resection. The group 
was divided in clinical stage A-D according 
to Flocks (Figs. 3, 4) and based on the his- 
tologic examination in grade I-IV (Figs. 5 , 6 ) .  
Hyperexcretion of NEC was present in 44.8% 
of stage A and B and in 52.6% of stage C 
and D; elevated T C  values were detected in 
52.2% and 63.2% respectively. 
Both parameters did not show any correla- 
tion to histological findings. It was remarkable 
that even in stage A NEC and T C  hyperexcre- 
tion occurred; in all of these patients levels 
of serum acid phosphatase were normal. 
Simultaneous determination of NEC and 
serum acid phosphatase gave a pathological 
result of at least one parameter in 51.7% of 
stage A and B and in 84.2% of stage C and D 
The association of enhanced serum acid 
phosphatase activity with prostatic neoplasms 
is well known; unfortunately, it is not suitable 
for detection of early clinical  stage^.'*^'^ Eleva- 
tion of urinary nonesterified cholesterol in pa- 
tients with prostatic cancer was first reported 
by Acevedo et a1.2 In a series of 32 patients, 
in 29 (91%) hyperexcretion of NEC was ob- 
served based on an upper normal limit of 1.2 
mg/24 hours. Nonesterified cholesterol seemed 
to be the major component, representing 
about 70% of total urinary cholesterol, but 
only in a few cases have NEC and T C  been 
determined simultaneously. In a comparative 
evaluation of serum acid phosphatase and 
total urinary cholesterol in prostatic cancer, 
Chu et ~ 1 . ~  found pathologic values of serum 
acid phosphatase (SAP) in 67% and of urinary 
cholesterol in 62%. When a combined deter- 
mination of these two assays was performed, 
in 86% of the patients with prostatic cancer 
at least one parameter was elevated. 
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FIG. 7 .  Comparable evaluation of serum acid phos- 
phatase and nonesterified urinary cholesterol in prostatic 
carcinoma. 
It was concluded that a simultaneous de- 
termination of these parameters is valuable in 
diagnosing patients with prostatic neoplasia. 
However, it has to be mentioned that all pa- 
tients except one had stage D carcinoma with 
diffuse osseous metastasis. 
The percentage of pathologic results is de- 
pendent on the upper normal limit of an assay. 
For urinary nonesterified cholesterol we classi- 
fied all values below 2.2 mgl24 hours as 
normal. The higher percentage of elevated 
NEC values in prostatic carcinoma described 
by Acevedo et a1.2 is caused by the lower upper 
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FIG. 8. Comparable evaluation of serum acid phos- 
phatase and total urinary cholesterol in prostatic car- 
cinoma. 
normal limit of 1.2 mg/24 hours, which might 
be due to methodological differences. The rate 
of pathological urinary total cholesterol values 
in prostatic neoplasms reported by Chu et al.' 
was very similar to those for stage C and D 
presented in this study, due to the nearly 
identical upper normal limit of 2.6 mg/24 
hours in comparison to 2.9 mg/24 hours. Con- 
sequently we found in stage C and D a nearly 
identical rate of elevated values for simulta- 
neous determination of SAP and total urinary 
cholesterol. 
In benign prostatic hyperplasia stage 0- 1, 
urinary cholesterol values were normal. How- 
ever, the presence of residual urine in BPH 
was associated in a considerable percentage 
with pathologic NEC and TC levels. In all 
the latter patients the diagnosis was done from 
tissue obtained by T U R ,  there was no evidence 
of cancer in the samples examined. The pos- 
sibility of "occult" prostatic carcinoma being 
at least in part responsible for the observed 
pathologic urinary cholesterol levels could be 
not completely excluded, since such a diagnosis 
is done at autopsy and the complete gland 
has to be studied. 
In discussing the clinical value of the NEC 
and TC test in the diagnosis of prostatic can- 
cer, one has to consider that elevated urinary 
cholesterol levels had been detected in other 
diseases too, although the scientific value of 
older studies is limited due to the inadequate 
analytical techniques, as well as in some cases, 
to gross deficiency in patient s e l e c t i ~ n . ~ ~ ~ ~ ~ ~ ~ * ~ ~ -  
6 3 9 3 1 0 , 1 2 ~ 1 7 ~ 1 8  Hyperexcretion of urinary choles- 
terol in males occurred in patients with pluri- 
potential malignant testicular neoplasms and 
benign or malign diseases of kidney and uri- 
nary t r a ~ t . ~ , ' ~ , ' ~ , ' ~ ~ ' ~  If these diseases and BPH 
with residual urine can be excluded with rea- 
sonable certainty, NEC or TC determinations 
may be valuable in the diagnosis of prostatic 
cancer even in the early clinical stages of the 
disease, especially when in combination with 
serum acid phosphatase. 
The physiologic mechanisms of urinary 
cholesterol excretion are not known; Acevedo 
et al. suggested an excretion as a protein bound 
comp1ex.l Hyperexcretion in nephrotic syn- 
drome is possibly caused by increased glomer- 
ular filtration of plasma lipoproteins es- 
pecially HDL fraction.15 If elevated urinary 
cholesterol is present without incidence of dis- 
ease in the kidney and urinary tract, as in 
the case of prostatic carcinoma, higher pro- 
duction of specific lipoproteins by the malig- 
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nant cells may be discussed. In patients with 
prostatic adenoma, the presence of residual 
urine could be responsible for the observed 
elevated urinary cholesterol values. 
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